AB079. A next generation sequencing parallel biopsy protocol
Printed Abstract

AB079. A next generation sequencing parallel biopsy protocol

Jing Li, Yinghao Sun, Xu Gao, Yan Wang, Min Qu

Department of Urology, Changhai Hospital, Shanghai 200000, China

Background: Prostate biopsy is a main way for cancer detection and management, which is commonly performed in clinic and over 1 million procedures performed per year in Europe and the united states. The potential for biobanking of these specimens as valuable addition

Methods: After informed consent as part of an IRB approved protocol, ultrasound-guided biopsies of prostate cancer loci were performed on 18 consecutive cancer patients. Each locus is repeated biopsy and fresh tissues were transported on wet ice to Pathology and Center for Translational Medicine. After confirmation and evaluation of tumor content by professional pathologist, a minimum of 30 ng DNA of repeated biopsy loci was extracted for sequencing. Corresponding germline DNA from blood is extracted and used to prepare sequencing libraries for different purpose. Sequencing was performed using Illumina NextSeq500 under rapid run mode (average duration 1.5 days).

Results: We achieved 100% success rate in obtaining high-quality material for next-generation sequencing (NGS) using biopsy prostate sites. The amount of extracted DNA ranged between 0.302 and 2.292 µg. On average, 99.5% of paired-end reads generated have been mappable, confirming the high quality of extracted DNA and RNA, respectively.

Conclusions: We have developed a reliable approach to validate an effective biopsy protocol that increases the efficiency and quality of tumor samples for NGS sequencing. The essential role of the pathologist is highlighted. This protocol has been implemented for Precision Medicine Project in our institute, thus demonstrating wide applicability.

Keywords: Prostate

doi: 10.21037/tau.2018.AB079

Cite this article as: Li J, Sun Y, Gao X, Wang Y, Qu M. A next generation sequencing parallel biopsy protocol. Transl Androl Urol 2018;7(Suppl 5):AB079. doi: 10.21037/tau.2018.AB079